Our results also demonstrated that the EGFR pathway was activated in NSCLC cells sublines with acquired PTX resistance and that the PTX resistance was dramatically reduced when erlotinib was treated in combination with PTX. This evidence concerns the gene EGFR and non-small cell lung carcinoma.